Abstract
A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged
| Original language | English |
|---|---|
| Pages (from-to) | 1802-1811 |
| Number of pages | 10 |
| Journal | Leukemia |
| Volume | 21 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2007 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Cancer Research
Cite this
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support : A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). / Tarella, C.; Zanni, M.; Di Nicola, M.; Patti, C.; Calvi, R.; Pescarollo, A.; Zoli, V.; Fornari, A.; Novero, D.; Cabras, A.; Stella, M.; Comino, A.; Remotti, D.; Ponzoni, M.; Caracciolo, D.; Ladetto, M.; Magni, M.; Devizzi, L.; Rosato, R.; Boccadoro, M.; Bregni, M.; Corradini, P.; Gallamini, A.; Majolino, I.; Mirto, S.; Gianni, A. M.
In: Leukemia, Vol. 21, No. 8, 08.2007, p. 1802-1811.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support
T2 - A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)
AU - Tarella, C.
AU - Zanni, M.
AU - Di Nicola, M.
AU - Patti, C.
AU - Calvi, R.
AU - Pescarollo, A.
AU - Zoli, V.
AU - Fornari, A.
AU - Novero, D.
AU - Cabras, A.
AU - Stella, M.
AU - Comino, A.
AU - Remotti, D.
AU - Ponzoni, M.
AU - Caracciolo, D.
AU - Ladetto, M.
AU - Magni, M.
AU - Devizzi, L.
AU - Rosato, R.
AU - Boccadoro, M.
AU - Bregni, M.
AU - Corradini, P.
AU - Gallamini, A.
AU - Majolino, I.
AU - Mirto, S.
AU - Gianni, A. M.
PY - 2007/8
Y1 - 2007/8
N2 - A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged
AB - A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged
UR - http://www.scopus.com/inward/record.url?scp=34447626101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34447626101&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2404781
DO - 10.1038/sj.leu.2404781
M3 - Article
VL - 21
SP - 1802
EP - 1811
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 8
ER -